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CytokinesAbstract Background: A progressive pulmonary involvement is frequent in systemic sclerosis and
it is the leading cause of morbidity and mortality. IL-6 has been implicated in the pathogenesis of
systemic sclerosis via stimulation of ﬁbroblasts to produce excess collagen and glycosaminoglycan.
Speciﬁc correlation between IL-6 and lung involvement have not been found yet.
Aim: To study the possible correlation between lung involvement (assessed by spirometry and
HRCT abnormalities) and the serum level of IL-6.
Subjects and methods: 20 patients with scleroderma compared with 20 matched volunteers as
control group. All participants underwent spirometry, HRCT scan and serum IL-6 measurements.
HRCT signs were scored according to Warrick et al. score for systemic sclerosis.
Results: Patients showed a statistically signiﬁcant reduction in FVC%, FEF 25–75% and signif-
icantly higher ESR and IL-6 compared to control. There was a highly signiﬁcant positive correla-
tion between the total HRCT score and serum IL-6.
Conclusion: Serum IL-6 could be a marker of the degree of pulmonary involvement in patients
with systemic sclerosis.
ª 2014 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis.Introduction
Systemic sclerosis (SS) is a diffuse connective tissue disease of
unknown etiology, characterized by skin and visceral ﬁbrosis,
vascular dysfunction, and circulating autoantibodies [1]. Pul-
monary involvement is frequent in SS. It is reported in 70%
[2] to 100% [3] of patients in autopsy series.
Several cytokines and chemokines have been implicated in
the induction of ﬁbrosis, but a deﬁnitive relationship between
speciﬁc cytokines and some organ involvement has not been
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kines, has been implicated in the pathogenesis of SS. IL-6
expression is reportedly high in both the skin and serum of
SS patients [5], and its elevation depends on the skin score [6].
Open lung biopsy remains the gold standard to diagnose
interstitial lung disease, high resolution CT (HRCT) is consid-
ered to be the reference among the noninvasive procedures. It
allows very precise analysis of lung parenchyma, with the
advantage of assessing lung volumes [7]. Interstitial signs on
HRCT are not equal in signiﬁcance. Honeycombing, for exam-
ple, has a worse prognosis than ground-glass appearance [8].
Warrick et al. [9] have deﬁned a score based on the criteria
of type and extent of HRCT signs in SS patients. The aim of
this study is to study the possible correlation between lung
involvement {assessed by spirometry and HRCT abnormali-
ties} and the serum level of IL-6 in SS patients.
Patients and methods
Twenty patients (6 males and 14 females) with SS were
recruited from the rheumatology outpatient clinic in Mino-
uﬁya University Hospital during the period from Oct 2012 to
Oct 2013 and 20 age and sex- matched apparently healthy con-
trol subjects. All patients fulﬁlled the criteria proposed by the
American College of Rheumatology [10]. None of the patients
had recent symptoms or signs of lower respiratory infection at
the time of the study. Known histories of asthma, allergic alve-
olitis, or exposure to organic dusts were exclusion criteria.
Informed consent and ethical approval from Minouﬁya Uni-
versity Hospital Ethics Committee were obtained from all par-
ticipants before enrollment.
Pulmonary function test
Pulmonary function tests (PFT) were done for all the patients
in the pulmonary function test unit in Minouﬁya University
Hospital using spirometer (Quark PFT3, COSMED, Italy)
All measurements were performed according to the American
Thoracic Society recommendations and expressed as percent
of predicted values based on age, sex and height. Clinically sig-
niﬁcant restrictive lung disease was deﬁned when an abnormal
FVC with normal FEV1/FVC was observed [11].
HRCT scanning
All participants underwent a HRCT scan of the chest. HRCT
scans were read by two independent radiologists in random
order, without knowledge of the results of the other’s ﬁndings.
A consensuswas obtained in all cases after a common third read-
ing. The parenchymal abnormalities identiﬁed on HRCT were
coded and a score was deﬁned according to Warrick et al. [9].
A point value was assigned to each abnormality (ground-glass
appearance, (1) irregular pleural margins, (2) septal/sub-pleural
lines, (3) honeycombing, (4) sub-pleural cysts and (5)). For each
patient, a ‘‘severity of disease’’ score was obtained by adding
these point values. An ‘‘extent of disease’’ score was obtained
by counting the number of bronchopulmonary segments
involved for each abnormality: 1–3 segments scored 1; 4–9 seg-
ments scored 2; >9 segments scored 3. Finally, severity of dis-
ease and extent of disease scores were added to form a total
HRCT score, with a possible range of 0–30.IL-6
Serum IL-6 levels were examined by ELISA, as described by
manufacturer (Biosource, Nivelles, Belgium); fasting venous
blood samples were taken from all participants when HRCT
or PFTs were carried out.
Statistical analysis
Data were analyzed by the SPSS version 13.0 statistical pack-
age. Categorical and quantitative variables were respectively
described as numbers, percentage (%) and mean ± standard
deviation (SD). Between-group comparisons were performed
using Student’s t test for variables with a normal distribution
and the Mann–Whitney U-test for variables with a non-normal
distribution. Correlation between variables was calculated by
Pearson correlation coefﬁcient. P values < 0.05 were consid-
ered statistically signiﬁcant.
Results
This study was conducted on 20 patients with SS (6 males and
14 females) and another 20 control subjects (8 males and 12
females). The FVC% and FEF 25–75% were signiﬁcantly
lower in the patients compared to controls. There was no sig-
niﬁcant difference between the two groups regarding age, sex
and FEV1/FVC Table 1.
There were signiﬁcantly higher values of ESR, CRP, Anti
Scl-70 and IL-6 in patients compared to controls Table 2.
In the studied patients, there was a signiﬁcantly positive
correlation between serum IL-6 level and each of CRP, Anti
Scl-70 and HRCT score. Table 3, Figs. 1–3.Discussion
Several lines of evidences indicate that SS presents deregulated
production of cytokines implicated in vascular damage and
ﬁbrosis, but their relationship with clinical ﬁndings is still
unclear. We studied the possible correlation between lung
involvement (assessed by PFT and HRCT abnormalities)
and the serum level of IL-6. We found signiﬁcantly higher lev-
els of serum IL-6 in patients with SS compared to controls
(Table 2).Moreover, serum IL-6 correlated positively with Anti
Scl-70 (Table 3, Fig. 3). This goes in agreement with several
studies [5,12–14]. IL-6 is a pleiotropic cytokine with multiple
biological effects on immune regulation, haematopoiesis,
inﬂammation, oncogenesis [15–20]. Several authors [12,13,21]
have demonstrated increased production of IL-6 by ﬁbroblasts
in SS patients. Duncan et al. [22] study showed furthermore
increased production of collagen and glycosaminoglycans,
hyaluronic acid and chondroitin-4/6-sulfates from human der-
mal ﬁbroblasts induced by IL-6 suggesting a role for IL-6 in
promoting ﬁbrosis, and increased levels of IL-6 have been
reported in the serum, bronchoalveolar lavage, and skin biop-
sies of patients with SS [5,18,21,23]. Moreover, Lung ﬁbrosis
induced by irradiation or bleomycin therapy is attenuated in
IL-6 gene knockout mice [24].
The present study demonstrated a highly signiﬁcant posi-
tive correlation between serum IL-6 and CRP (Table 3,
Fig. 2). This is in agreement with Alegre-Sancho et al. [25]
Table 1 Demographic and Spirometric data of the studied groups.
The studied groups Test of signiﬁcance P value
Cases No = 20 Controls No = 20
Age (years) Mean ± SD 34.60 ± 11.82 34.70 ± 11.12 t-test = 0.02 0.98
Male (N, %) 6 (30%) 8 (60%) v2 = 0.44 0.51
FVC% (Mean ± SD) 64.60 ± 26.45 88.35 ± 5.37 Mann Whitney U-test = 2.89 0.004*
FEV1/FVC (Mean ± SD) 87.80 ± 6.46 87.20 ± 4.87 t-test = 0.33 0.74
FEF 25–75% (Mean ± SD) 58.80 ± 16.65 80.90 ± 8.19 t-test = 5.3 0.001*
FVC: forced vital capacity, FEV1: forced expiratory ﬂow in the ﬁrst second, FEF 25–75%: forced expiratory ﬂow 25–75%.
* Statistically signiﬁcant (P< 0.05).
Table 2 Laboratory values of the studied groups.
The studied groups t-test P value
Cases No = 20 Controls No = 20
ESR mm (Mean ± SD) 26.7 ± 16.96 5.55 ± 2.31 5.52 0.000**
CRP mg/L (Mean ± SD) 18.5 ± 13.79 3.72 ± 1.65 4.76 0.000**
Anti Scl-70 U/ml (Mean ± SD) 32 ± 7.49 8.55 ± 2.79 13.1 0.000**
IL-6 pg/ml (Mean ± SD) 5.55 ± 3.92 1.49 ± 1.87 4.18 0.000**
ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, Anti Scl-70; anti scleroderma-70.
** Statistically highly signiﬁcant (P< 0.001).
Table 3 Correlation between IL-6 and other parameters in the
studied patients.
IL-6
r P-Value
Age 0.40 0.078
ESR 0.19 0.93
CRP 0.91 0.000**
Anti Scl-70 0.90 0.000**
FVC% 0.31 0.19
FEV1/FVC 0.64 0.20
FEF 25–75% 0.29 0.22
Chest HRCT score 0.97 0.000**
ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, Anti
Scl-70; anti scleroderma-70, FVC: forced vital capacity, FEV1:
forced expiratory ﬂow in the ﬁrst second, FEF 25–75%: forced
expiratory ﬂow 25–75%, HRCT: High resolution CT.
*Statistically signiﬁcant (P< 0.05).
** Statistically highly signiﬁcant (P< 0.001).
Figure 1 Correlation between IL-6 and HRCT score in the
studied patients.
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moderate correlation with high-sensitivity CRP level. CRP
level is a general marker of inﬂammation. It is a part of the
innate immune response to systemic inﬂammation [27]. IL-6
and CRP have related roles in the inﬂammatory response:
IL-6 induces CRP production in the liver by activating Janus
kinases. Signal transducers and activators of transcription sub-
sequently switch on the CRP gene expression, leading to the
production of CRP [28]. CRP and/or ESR have been linked
to lung involvement in SS [29].
In the current study, there was a highly signiﬁcant positive
correlation between serum IL-6 and HRCT score (Table 3,
Fig. 1). This matches the results of De Santis et al. [30] study.
Although they used a different HRCT scoring system as
described by Kazerooni et al. [31] They demonstrated a signif-icantly positive correlation between HRCT score and IL-6
plasma level (r= 0.36, P= 0.0012) suggesting that patients
with a greater extent of lung affection on HRCT had a more
aggressive disease. In addition, higher IL-6 plasma levels sug-
gest that inﬂammation could explain the more aggressive pul-
monary disease in patients with alveolitis. Our results also
agree with Diot et al. [32] study who studied the abnormalities
on lung HRCT in 52 patients with SS using the Warrick et al.
[9] score and with reference to the PFT results of each patient.
They found that HRCT score was signiﬁcantly higher in
Figure 2 Correlation between IL-6 and CRP in the studied
patients.
Figure 3 Correlation between IL-6 and anti Scl-70 in the studied
patients.
240 M. Yousif et al.patients with diffuse SS than in those with limited SS. More-
over, HRCT score negatively correlated with diffusing capac-
ity (DLCO), total lung capacity (TLC) but not FVC.
There was no correlation between IL-6 and FVC, FEV1/
FVC nor FEF 25–75% (Table 3). These parameters are usually
affected later than declined DLCO which is the early PFT
abnormality encountered in patients with interstitial lung dis-
ease. De Santis et al. [30] study showed that serum IL-6 was
associated with DLCO decline but not FVC in SS, and there-
fore, they considered it a good biomarker of PFT affection
candidate to be investigated further. The analysis of their test
cohort showed that elevated IL-6 was predictive of a decline in
FVC and/or DLCO within the ﬁrst year, and of death within
the ﬁrst 30 months. They explained the lack of association with
progression at later time points by the fact that IL-6 might sig-nal the onset of phases of disease progression, rather than
mark different phenotypes of the disease constitutively charac-
terized by a different prognosis. In conclusion; Serum IL-6
measurement may be a noninvasive independent predictor of
lung involvement and progression in SS patients. Prospective
studies are needed to evaluate the exact role of IL-6 in lung
ﬁbrosis, to assess whether there could be a role for anti-IL-6
treatment in SS interstitial lung disease.
A number of limitations should be considered when inter-
preting our ﬁndings. There were no data regarding the dura-
tion of SS disease prior to study enrollment, no
differentiation of patients weather they have diffuse or limited
SS, No data about SS therapy, Pulmonary function tests did
not include DLCO.
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